MIXTURE FOR TRANSDERMAL DELIVERY OF LOW AND HIGH MOLECULAR WEIGHT COMPOUNDS
The present invention relates to the discovery of a transdermal delivery system that can deliver high molecular weight pharmaceuticals and cosmetic agents to skin cells. A novel transdermal delivery system with therapeutic and cosmetic application and methods of use of the foregoing is disclosed.
1 . A transdermal delivery system comprising:
an ethoxylated oil; and
a delivered agent mixed with said ethoxylated oil, wherein said ethoxylated oil contains between 10 and 19 ethoxylations/molecule.
2 . The transdermal delivery system of claim 1 , wherein said ethoxylated oil contains 16 ethoxylations/molecule.
3 . The transdermal delivery system of claim 1 , wherein said ethoxylated oil comprises an ethoxylated meadow foam oil.
4 . The transdermal delivery system of claim 1 , wherein said delivered agent is less than 1,000 daltons.
5 . The transdermal delivery system of claim 1 , wherein said delivered agent is 1,000 daltons or greater.
6 . The transdermal delivery system of claim 1 , wherein said delivered agent is a steroid.
7 . The transdermal delivery system of claim 1 , wherein said delivered agent is an antiviral compound.
8 . The transdermal delivery system of claim 1 , wherein said delivered agent is a nucleic acid.
9 . The transdermal delivery system of claim 1 , wherein said delivered agent is a peptide.
10 . The transdermal delivery system of claim 1 , wherein said delivered agent is a non-steroidal anti inflammatory drug (NSAID).
11 . The transdermal delivery system of claim 10 , wherein said non-steroidal anti inflammatory drug (NSAID) is selected from the group consisting of ibuprofen (2-(isobutylphenyl)-propionic acid); methotrexate (N-[4-(2, 4 diamino 6-pteridinyl-methyl]methylamino] benzoyl)-L-glutamic acid); aspirin (acetylsalicylic acid); salicylic acid; diphenhydramine (2-(diphenylmethoxy)-N,N-dimethylethylamine hydrochloride); naproxen (2-naphthaleneacetic acid, 6-methoxy-9-methyl-, sodium salt, (−)); phenylbutazone (4-butyl-1,2-diphenyl-3,5-pyrazolidinedione); sulindac-(2)-5-fluoro-2-methyl-1-[[p-(methylsulfinyl)phenyl]methylene-]-1H-indene-3-acetic acid; diflunisal (2′,4′, -difluoro-4-hydroxy-3-biphenylcarboxylic acid; piroxicam (4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-2-carboxamide 1,1-dioxide, an oxicam; indomethacin (1-(4-chlorobenzoyl)-5-methoxy-2-methyl-H-indole-3-acetic acid); meclofenamate sodium (N-(2,6-dichloro-m-tolyl) anthranilic acid, sodium salt, monohydrate); ketoprofen (2-(3-benzoylphenyl)-propionic acid; tolmetin sodium (sodium 1-methyl-5-(4-methylbenzoyl-1H-pyrrole-2-acetate dihydrate);
diclofenac sodium (2-[(2,6-dichlorophenyl)amino] benzeneatic acid, monosodium salt); hydroxychloroquine sulphate (2-{[4-[(7-chloro-4-quinolyl)amino] pentyl]ethylamino}ethanol sulfate (1:1); penicillamine (3-mercapto-D-valine); flurbiprofen ([1,1-biphenyl]-4-acetic acid, 2-fluoro-alphamethyl-, (+−)); cetodolac (1-8-diethyl-13,4,9, tetra hydropyrano-[3-4-13] indole-1-acetic acid; mefenamic acid (N-(2,3-xylyl)anthranilic acid; and diphenhydramine hydrochloride (2-diphenyl methoxy-N,N-di-methylethamine hydrochloride).
12 . The transdermal delivery system of claim 1 , wherein said delivered agent is a collagen or fragment thereof.
13 . A method of transdermal delivery of a delivered agent comprising:
identifying a subject in need of transdermal delivery of a delivered agent; and
providing said subject a transdermal delivery system according to claim 1 .
14 . The method of claim 13 , wherein said transdermal delivery system comprises a delivered agent that is less than 1,000 daltons.
15 . The method of claim 13 , wherein said transdermal delivery system comprises a delivered agent that is 1,000 daltons or greater.
16 . The method of claim 13 , wherein said transdermal delivery system comprises a delivered agent that is a steroid.
17 . The method of claim 13 , wherein said transdermal delivery system comprises a delivered agent that is an antiviral compound.
18 . The method of claim 13 , wherein said transdermal delivery system comprises a delivered agent that is a nucleic acid.
19 . The method of claim 13 , wherein said transdermal delivery system comprises a delivered agent that is a peptide.
20 . The method of claim 19 , wherein said delivered agent is a non-steroidal anti inflammatory drug (NSAID).
21 . The method of claim 20 , wherein said non-steroidal anti inflammatory drug (NSAID) is selected from the group consisting of ibuprofen (2-(isobutylphenyl)-propionic acid); methotrexate (N-[4-(2, 4 diamino 6-pteridinyl-methyl]methylamino] benzoyl)-L-glutamic acid); aspirin (acetylsalicylic acid); salicylic acid; diphenhydramine (2-(diphenylmethoxy)-N,N-dimethylethylamine hydrochloride); naproxen (2-naphthaleneacetic acid, 6-methoxy-9-methyl-, sodium salt, (−)); phenylbutazone (4-butyl-1,2-diphenyl-3,5-pyrazolidinedione); sulindac-(2)-5-fluoro-2-methyl-1-[[p-(methylsulfinyl)phenyl]methylene-]-1H-indene-3-acetic acid; diflunisal (2′,4′, -difluoro-4-hydroxy-3-biphenylcarboxylic acid; piroxicam (4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-2-carboxamide 1,1-dioxide, an oxicam; indomethacin (1-(4-chlorobenzoyl)-5-methoxy-2-methyl-H-indole-3-acetic acid); meclofenamate sodium (N-(2,6-dichloro-m-tolyl) anthranilic acid, sodium salt, monohydrate); ketoprofen (2-(3-benzoylphenyl)-propionic acid; tolmetin sodium (sodium 1-methyl-5-(4-methylbenzoyl-1H-pyrrole-2-acetate dihydrate); diclofenac sodium (2-[(2,6-dichlorophenyl)amino] benzeneatic acid, monosodium salt);
hydroxychloroquine sulphate (2-{[4-[(7-chloro-4-quinolyl)amino] pentyl]ethylamino}ethanol sulfate (1:1); penicillamine (3-mercapto-D-valine); flurbiprofen ([1,1-biphenyl]-4-acetic acid, 2-fluoro-alphamethyl-, (+−)); cetodolac (1-8-diethyl-13,4,9, tetra hydropyrano-[3-4-13] indole-1-acetic acid; mefenamic acid (N-(2,3-xylyl)anthranilic acid; and diphenhydramine hydrochloride (2-diphenyl methoxy-N,N-di-methylethamine hydrochloride).
22 . The method of claim 13 , wherein said transdermal delivery system comprises a collagen or fragment thereof.
23 . The method of claim 13 , further comprising; observing said subject for a response to said delivered agent, after providing said transdermal delivery system.
24 . A method of reducing pain or inflammation comprising:
identifying a subject in need of a reduction in pain or inflammation; and
providing said subject a transdermal delivery system according to claim 10 .
25 . A method of reducing wrinkles in the skin comprising:
identifying a subject in need of a reduction in wrinkles in the skin; and
providing to said subject a transdermal delivery system according to claim 1 .
26 . The method of claim 25 , further comprising observing a reduction of wrinkles in the skin of said subject.
27 . The method of claim 25 , wherein said transdermal delivery system comprises a collagen or fragment thereof.
28 . A method of restoring skin tone comprising:
(a) identifying a subject in need of a restoration of skin tone; and
(b) providing to said subject a transdermal delivery system according to claim 12 .
29 . The method of claim 28 , further comprising observing a restoration of skin tone in said subject.
30 . A method of increasing skin tightness comprising:
identifying a subject in need of skin tightness; and
providing to said subject a transdermal delivery system according to claim 1 .
31 . The method of claim 30 , further comprising observing an increase in skin tightness in said subject.
32 . A method of providing a peptide to a subject comprising:
(a) identifying a subject in need of said peptide; and
(b) providing said subject the transdermal delivery system of claim 1 , wherein said delivered agent comprises a peptide that comprises the sequence LKEKK (SEQ. ID. No. 1).
33 . The method of claim 32 , further comprising;
observing said subject for a response to said peptide, after providing said transdermal delivery system.